Last reviewed · How we verify
NCT05363488
Retrospective Observational Research Study to Describe the Real World Use of Bosutinib in a Single Centre in Scotland
trial testing Bosutinib in Myeloid Leukemia in 17 participants. Completed in 8 October 2021.
8 October 2021
Quick facts
| Lead sponsor | Pfizer |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 17 |
| Start date | 8 October 2021 |
| Primary completion | 8 October 2021 |
| Estimated completion | 8 October 2021 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- Bosutinib (bosutinib) — full drug profile →
Conditions studied
- Myeloid Leukemia — all drugs for Myeloid Leukemia →
Sponsor
Pfizer — full company profile →
Who can join
18 and older, any sex, with Myeloid Leukemia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will describe the efficacy and safety of bosutinib in patients with chronic myeloid leukaemia (CML) used in a real world clinical practice setting.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05363488
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Bosutinib
Trials testing the same drug.
- NCT04877522 — Asciminib Roll-over Study · Phase 4 · recruiting
- NCT05032690 — Evaluation of the Relative Bioavailability of Bosutinib Capsules Under Fed Condition and Estimation of Food Effect on Or · Phase 1 · completed
- NCT04971226 — A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP · Phase 3 · active not recruiting
- NCT05286528 — Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of · completed
- NCT04578847 — A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib) · Phase 2 · unknown
Other recruiting trials for Myeloid Leukemia
Currently open trials in the same condition.
- NCT06235801 — A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid L · Phase 1, PHASE2 · recruiting
- NCT06130579 — Interferon-α for TP53 Myeloid Malignancy Post Allo-HSCT · Phase 2 · recruiting
- NCT05194397 — Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors · Phase 2 · recruiting
- NCT05035706 — Anti-Leukemia Immune Responses After Irradiation of Extramedullary Tumors · EARLY_PHASE1 · active not recruiting
- NCT04260022 — Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL · Phase 1 · recruiting
Other Pfizer trials
Trials by the same sponsor.
- NCT04982848 — Korea Post Marketing Surveillance (PMS) Study of Talzenna® · not yet recruiting
- NCT06873191 — A Study to Learn More About Tukysa Once it is Out in the Korean Market · not yet recruiting
- NCT07497854 — A Study to Learn About the Study Medicine NURTEC® ODT 75 mg After it is Released Into the Markets in Korea · not yet recruiting
- NCT06507904 — A Study to Learn How Different Preparations of Osivelotor Taste and Enter the Blood With Food or Liquids or With an Anta · Phase 1 · not yet recruiting
- NCT06864585 — A Study to Learn About the Study Medicine - Zavicefta in Patients With Sepsis or Loss of Kidney Function in Japan · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05363488 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Pfizer
- Last refreshed: 3 April 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05363488.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing